• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of surgery and medicine. >An effective method to reduce the risk of endophthalmitis after intravitreal injection (IVI): Application of 0.25% povidone-iodine
【24h】

An effective method to reduce the risk of endophthalmitis after intravitreal injection (IVI): Application of 0.25% povidone-iodine

机译：玻璃体内注射液（IVI）后降低内腔炎风险的有效方法：0.25％Povidone-碘的应用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: The most important complication after intravitreal injection (IVI) is endophthalmitis, which can result in severe vision loss. This study aims to investigate the effect of 0.25% povidone-iodine (PI) application before IVI on the incidence of endophthalmitis in patients who received intravitreal antivascular endothelial growth factor (anti-VEGF) injection. Methods: A total of 15345 intravitreal anti-VEGF injections and nine endophthalmitis cases after IVI performed at the outpatient injection room of a single university hospital between January 2017 and January 2020 were included in this retrospective cohort study. Before July 2018, after applying 10% PI around the eyes and 5% PI on the eyes, an eyelid speculum was inserted, and the injection was performed. After this date, in addition to these steps, after placing a speculum and determining the injection site with a caliper, 3-4 drops of 0.25% PI were applied just before injection. Topical antibiotics were not used before or after the injection. Results: Nine cases of endophthalmitis were detected in 3 years. The most common symptoms were vision loss (9/9) and pain in the eye (7/9). All cases had conjunctival hyperemia, cells-hypopyon in the anterior chamber, and cells in the vitreous. The time between injection and re-visiting the clinic due to endophthalmitis symptoms ranged between 2-6 days, and visual acuity varied between hand motion and 0.2. While the number of endophthalmitis cases before July 2018 was 8 (8/8330) in 1.5 years, after the addition of 0.25% PI application to the protocol, only 1 case of endophthalmitis (1/7015) was seen in the last 1.5 years. The rate of endophthalmitis had decreased significantly (P=0.037). Conclusion: Since July 2018, the addition of 0.25% PI to the standard IVI protocol just before injection has significantly reduced endophthalmitis rates. With this method, endophthalmitis rates may be decreased despite the increasing number of IVIs.
机译：背景/目的：玻璃体内注射（IVI）之后最重要的并发症是眼内炎，这可能会导致严重的视力丧失。本研究旨在探讨0.25％碘伏（PI）应用程序的IVI之前，眼内炎的发病率谁收到玻璃体内抗血管内皮生长因子（抗VEGF）注入患者的影响。方法：共有15345玻璃体内的抗VEGF注射和九眼内炎病例后IVI在2017年1月和一月至2020年一所大学医院的门诊注射室进行被列入这项回顾性队列研究。 2018年7月之前，对眼睛将眼睛周围的10％PI和5％PI后，眼睑窥器插入，并进行注射。此日期之后，除了这些步骤，放置窥器以及确定注射部位用卡尺后，0.25％PI 3-4滴刚刚注射之前施加。外用抗生素之前或在注射后不采用。结果：在3年内进行检测眼内炎的9例。最常见的症状是视力减退（9/9）和疼痛的眼睛（7/9）。所有病例结膜充血，细胞，前房积脓前房和细胞玻璃体。由于眼内炎症状注射和再逛诊所之间的时间2-6天之间的范围内，并且手部运动和0.2之间视力变化。而眼内炎病例2018年7月之前的数目。5年为8（8330分之8），添加0.25％的PI应用到协议后，仅1（7015分之1）的情况下眼内炎的主要出现在最后5年。眼内炎的速率已显著降低（P = 0.037）。结论：由于2018年7月，在加入0.25％PI到标准IVI协议只是注射之前已显著降低眼内炎率。使用这种方法，眼内炎费率可能，尽管越来越多的IVIS的减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号